Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
出版年份 2022 全文链接
标题
Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 16, Pages 9417
出版商
MDPI AG
发表日期
2022-08-22
DOI
10.3390/ijms23169417
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE)
- (2022) Martin J. O’Donnell et al. Journal of Stroke
- Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
- (2022) Stephen J. Nicholls et al. NATURE MEDICINE
- Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease
- (2022) Arjen J. Cupido et al. JAMA Cardiology
- Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
- (2021) Camilla Ditlev Lindhardt Johannesen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease
- (2021) Michael G. Levin et al. CIRCULATION
- Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
- (2021) Nick S Nurmohamed et al. CARDIOVASCULAR RESEARCH
- Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
- (2021) et al. EUROPEAN HEART JOURNAL
- Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis
- (2021) Nicholas A. Marston et al. JAMA Cardiology
- Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis
- (2020) Tom G. Richardson et al. PLOS MEDICINE
- Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
- (2020) Mark P. Metzinger et al. Journal of the American Heart Association
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2019) Scott M. Grundy et al. CIRCULATION
- What is ‘LDL cholesterol’?
- (2019) Michael V. Holmes et al. Nature Reviews Cardiology
- Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
- (2019) Jane Armitage et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data from UK Biobank
- (2019) Claire Welsh et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Apolipoprotein B Particles and Cardiovascular Disease
- (2019) Allan D. Sniderman et al. JAMA Cardiology
- Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease
- (2018) L. Bowman et al. JOURNAL OF VASCULAR SURGERY
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
- (2017) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease
- (2017) Michael V. Holmes et al. Nature Reviews Cardiology
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trials and Tribulations of CETP Inhibitors
- (2017) Alan R. Tall et al. CIRCULATION RESEARCH
- Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
- (2016) John S. Millar et al. JOURNAL OF CLINICAL INVESTIGATION
- Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification
- (2016) John T. Wilkins et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) G Kees Hovingh et al. LANCET
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C
- (2015) Michael J Pencina et al. European Journal of Preventive Cardiology
- Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
- (2014) John Ford et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
- (2014) S. Kuhnast et al. EUROPEAN HEART JOURNAL
- Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
- (2014) Navjot Kaur et al. PLoS One
- Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
- (2014) George Thanassoulis et al. Journal of the American Heart Association
- Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease
- (2013) Antonio M. Gotto et al. AMERICAN JOURNAL OF CARDIOLOGY
- Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT/QTc Study in Healthy Participants
- (2013) Jeffrey G. Suico et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study
- (2012) Allan D. Sniderman et al. ATHEROSCLEROSIS
- Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
- (2012) S. Matthijs Boekholdt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors
- (2012) Shenping Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
- (2012) Michael Davidson et al. JOURNAL OF LIPID RESEARCH
- Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
- (2012) Trine Holm Johannsen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Torcetrapib impairs endothelial function in hypertension
- (2011) Branko Simic et al. EUROPEAN HEART JOURNAL
- Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
- (2011) Guoqing Cao et al. JOURNAL OF LIPID RESEARCH
- When is equal not equal?
- (2010) Allan D. Sniderman et al. Journal of Clinical Lipidology
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction
- (2009) Paul M. Ridker et al. Circulation-Cardiovascular Genetics
- Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
- (2009) Xiao Hu et al. ENDOCRINOLOGY
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
- (2008) Alexander Thompson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started